I agree with you there. Market cap is the important comparison....

I agree with you there. Market cap is the important comparison. The initial rerate would be around $15 / share, but I expect ARDs/COVID approval to get us well above - $100-200 per share wouldn't be out of the question as it is a significantly larger market. Add on CLBP and heart = even larger markets. The only question everyone needs to ask themselves is what odds they assess the chance of approval for SR-aGVHD (or risk of not getting approved), then the odds of a subsequent ARDs/COVID approval, then the odds of a subsequent CLBP approval, then the odds of a subsequent heart approval, then the odds of MIS-C approval, then the odds of Crohns approval, then the odds of etc etc etc. Many things would have to go wrong for you to lose money here IMO. Inflammation is present in almost any disease process, and a significant cause of disease as well. I feel this is the beginning of a domino effect, one that there is only one front runner in the entire market, everyone else just getting their horsies saddled. Each to their own, make your own risk assessments. Good luck all!